Top Markets
#1 Glidr Glidr +51.75%
#2 DOVU DOVU +47.62%
#3 Akedo Akedo +40.17%
#4 Velvet Velvet +38.60%
#5 Black Phoenix Black Phoenix +34.09%
#6 Cross Cross +26.08%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.46%
#8 Perle Perle +15.86%
#9 Bitway Bitway +15.33%
#10 QANplatform QANplatform +14.56%
Coin of the day
Glidr Glidr
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
VivoSim Labs, Inc. VivoSim Labs, Inc.

VivoSim Labs, Inc.

VIVS
Classifica tra le azioni #38702
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company,... VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Prezzo delle azioni
$0.3248
Capitalizzazione di mercato
$834.29K
Variazione (1 giorno)
-1.01%
Variazione (1 anno)
-81.96%
Paese
US
Scambia VivoSim Labs, Inc. (VIVS)

Categoria

Healthcare
Ricavi di VivoSim Labs, Inc. (VIVS)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di VivoSim Labs, Inc., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per VivoSim Labs, Inc. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE